Floatz logo

5-FLUOROURACIL-1.BETA.-D-RIBOFURANOSIDE

Rectal Cancer

Shanghai Minimally Invasive Surgery CenterSmall moleculePhase 1/2Active
CC
43/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
33/ 100
Competitive Position
73/ 100

Competitive context

94 Active assets in the Rectal Cancer cohort.

Asset / SponsorPhaseRating
Capecitabine
Gustave Roussy, Cancer Campus, Grand Paris
Phase 4BBB
Calcium folinate pentahydrate
Gustave Roussy, Cancer Campus, Grand Paris
Phase 3BBB
Eloxatin
Gustave Roussy, Cancer Campus, Grand Paris
Phase 3BBB
FLUOROURACILUM
Gustave Roussy, Cancer Campus, Grand Paris
Phase 3BBB
Irinotecan
SCRI Development Innovations, LLC
Phase 3BB

View all 50 →

Same molecule, other indications

5-FLUOROURACIL-1.BETA.-D-RIBOFURANOSIDE is also rated in:

Neoadjuvant TreatmentDormant
CCC
Indicative ·
48 / 100
View asset →
cancerDormant
CC
Indicative ·
46 / 100
View asset →
BevacizumabDormant
CC
Indicative ·
45 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →